A 39-year-old male with symptomatic hypogonadism on testosterone therapy presents to the emergency department at the request of his primary care physician after outpatient labs showed a hemoglobin of 22.0 g/dl. He denies chest pain, shortness of breath, extremity swelling, or neurologic symptoms such as changes in vision, motor function, or sensation. On evaluation, his vital signs and a detailed physical examination are normal. There are no other lab abnormalities.

The patient was discharged with outpatient primary care follow-up after collection of serum EPO and JAK2 levels – the former of which was elevated and findings were attributed to testosterone use.

Algorithm for the Evaluation of Erythrocytosis

References

1. Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification, and management. American Journal of Hematology. 2019;94(1):133-143. doi:10.1002/ajh.25303
2. McMullin MF, Harrison CN, Ali S, et al. A guideline for the diagnosis and management of polycythaemia vera. British Journal of Haematology. 2019;184(2):176-191. doi:10.1111/bjh.15648
3. Tintinalli JE, Ma OJ, Yealy DM, et al., eds. Tintinalli’s Emergency Medicine: A Comprehensive Study Guide. 9th ed. McGraw-Hill Education; 2020.

The post Erythrocytosis appeared first on Differential Diagnosis of.

A 65-year-old male with a past medical history of hypertension, diabetes mellitus, and atrial fibrillation presents after a mechanical fall with a posterior scalp hematoma and altered mental status. The patient’s family reports that the patient is taking apixaban with his last dose 4 hours prior to arrival. Physical examination reveals a GCS of 13, blood pressure of 175/99, and asymmetric pupils. The patient is taken to CT where head imaging reveals left sided subdural hematoma with midline shift and developing uncal herniation.

A nicardipine infusion is initiated and the head of the bed is elevated. Andexanet Alfa is not available, therefore an infusion of 4-Factor PCC is initiated. The patient is taken emergently to the operating room by neurosurgery for craniotomy and hematoma evacuation.

An Algorithm for the Reversal of Anticoagulation for Intracranial Hemorrhage ^1-4

All Agents

For all agents, discontinue anticoagulation. Patients may require blood pressure control including anti-hypertensive infusions (goal SBP <140). Avoid reversal for intracranial hemorrhage associated with cerebral venous thrombosis. Use cautiously in patients with concomitant life-threatening ischemia, thrombosis, or severe DIC.

Vitamin K Antagonists (ex. warfarin)

Initial Dose

A fixed dose of 4F-PCC 1500 to 2000 units can be given as an initial dose with repeat dosing based on INR measurement 15 minutes after completion of infusion. Follow local institution guidelines if available.

Monitoring and Repeat Dosing

• Vitamin K: if INR ≥1.4 at 12 hours ⁵
• 4F-PCC: May consider repeat PCC dosing based on INR, though with increased DIC and thrombotic risk, it is recommended to correct further with FFP if INR remains ≥1.4 ⁶

Direct Factor Xa Inhibitors (ex. rivaroxaban, apixaban)

Activated charcoal may be effective for up to six hours for apixaban ⁷ and eight hours for rivaroxaban ⁸.

*Andexanet alfa Regimens ^9,10

• Low-dose: rivaroxaban <10mg, apixaban <5mg, edoxaban <30mg or 8 or more hours since last dose
• High-dose: If greater than above thresholds, or dose/timing unknown

Pentasaccharides (ex. fondaparinux)

Use high-dose Andexanet alfa regimen ¹²

Direct Thrombin inhibitors (ex. dabigatran)

Monitoring and Repeat Dosing

If ongoing significant bleeding after treatment, consider redosing idarucizumab and/or hemodialysis.

Alternative Regimens

If idarucizumab is not available, aPCC (50-80 units/kg) , 4F-PCC or 3F-PCC (50 units/kg) can be used in order of preference.

Unfractionated Heparin

Dosing

Determination of units of heparin is based on estimated active agent (half-life 1-2 hours)

• Protamine sulfate 1mg/100 units IV, maximum dose 50mg
• Alternatively, can give fixed dose of 25-50mg

Monitoring and Repeat Dosing

If aPTT is persistently elevated, repeat 0.5 mg/100 units

Low-Molecular Weight Heparin ¹³

Reversal is not indicated if more than 3-5 half-lives have passed since administration:

• Enoxaparin mean half-life: 4-5 hours
• Dalteparin mean half-life: 2.8 hours
• Nadroparin mean half-life: 3.7 hours

If bleeding persists, or renal insufficiency, repeat dose .5 mg/1 mg enoxaparin or .5 mg/100 anti-Xa units.

References

Guidelines & Reviews

1. Greenberg SM, Ziai WC, Cordonnier C, et al. 2022 guideline for the management of patients with spontaneous intracerebral hemorrhage: a guideline from the american heart association/american stroke association. Stroke. Published online May 17, 2022:101161STR0000000000000407.
2. Tomaselli GF, Mahaffey KW, Cuker A, et al. 2020 acc expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the american college of cardiology solution set oversight committee. J Am Coll Cardiol. 2020;76(5):594-622.
3. Frontera JA, Lewin JJ, Rabinstein AA, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the neurocritical care society and society of critical care medicine. Neurocrit Care. 2016;24(1):6-46.
4.  Freeman, W. David, Weitz, Jeffrey. “Reversal of anticoagulation in intracranial hemorrhage.” UpToDate. (2022) https://www.uptodate.com/contents/reversal-of-anticoagulation-in-intracranial-hemorrhage?search=anticoagulation%20reversal (Accessed on May 26, 2022)

Vitamin K Antagonists

5. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin k antagonists: american college of chest physicians evidence-based clinical practice guidelines(8th edition). Chest. 2008;133(6 Suppl):160S-198S.
6. Pabinger I, Brenner B, Kalina U, et al. Prothrombin complex concentrate (Beriplex p/n) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost. 2008;6(4):622-631.

Direct Factor Xa Inhibitors

7. http://packageinserts.bms.com/pi/pi_eliquis.pdf
8. https://www.bayer.com/sites/default/files/2020-11/xarelto-pm-en.pdf
9. Demchuk AM, Yue P, Zotova E, et al. Hemostatic efficacy and anti-fxa (Factor xa) reversal with andexanet alfa in intracranial hemorrhage: annexa-4 substudy. Stroke. 2021;52(6):2096-2105.
10. Cohen AT, Lewis M, Connor A, et al. Thirty-day mortality with andexanet alfa compared with prothrombin complex concentrate therapy for life-threatening direct oral anticoagulant-related bleeding. J Am Coll Emerg Physicians Open. 2022;3(2):e12655.
11. Scaglione F. New oral anticoagulants: comparative pharmacology with vitamin K antagonists. Clin Pharmacokinet. 2013;52(2):69-82.

Pentasaccharides (ex. fondaparinux)

12. Lu G, DeGuzman FR, Hollenbach SJ, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013;19(4):446-451.

Low-Molecular Weight Heparin

13. Fareed J, Hoppensteadt D, Walenga J, et al. Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practice. Clin Pharmacokinet. 2003;42(12):1043-1057.

The post Anticoagulant Reversal in Intracranial Hemorrhage appeared first on Differential Diagnosis of.

A 28 year-old female with a history of systemic lupus erythematosus and end-stage renal disease without access to scheduled hemodialysis presents to the emergency department with 1 week of worsening dyspnea, fatigue and leg swelling. Her symptoms are reminiscent of prior episodes resolving with hemodialysis. On evaluation, vital signs are normal and laboratory tests demonstrate microcytic anemia (Hb 5.9g/dL) but no hyperkalemia. A plain chest radiograph is normal and the patient ambulates without hypoxia.

The patient was deemed to not meet any requirements for emergent hemodialysis. One unit of packed red blood cells was ordered for transfusion for symptomatic anemia. During transfusion, the patient developed worsening dyspnea and was found to be hypertensive and hypoxic. A chest radiograph was obtained and is shown below.

Pulmonary vascular congestion and bilateral pleural effusions.

Algorithm for the Evaluation and Management of Transfusion Reactions

References

1. Carson JL, Triulzi DJ, Ness PM. Indications for and Adverse Effects of Red-Cell Transfusion. N Engl J Med. 2017;377(13):1261-1272. doi:10.1056/NEJMra1612789.
2. Delaney M, Wendel S, Bercovitz RS, et al. Transfusion reactions: prevention, diagnosis, and treatment. Lancet. 2016;388(10061):2825-2836. doi:10.1016/S0140-6736(15)01313-6.
3. Goel R, Tobian AAR, Shaz BH. Noninfectious transfusion-associated adverse events and their mitigation strategies. Blood. 2019;133(17):1831-1839. doi:10.1182/blood-2018-10-833988.
4. Osterman JL, Arora S. Blood product transfusions and reactions. Emerg Med Clin North Am. 2014;32(3):727-738. doi:10.1016/j.emc.2014.04.012.
5. Silvergleid AJ. Approach to the patient with a suspected acute transfusion reaction. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com (Accessed on September 01, 2019.)
6. Suddock JT, Crookston KP. Transfusion Reactions. January 2019.

The post Transfusion Reactions appeared first on Differential Diagnosis of.

A 43 year-old female with no reported medical history presents with shortness of breath. She notes 2 months of gradually worsening symptoms associated with unproductive cough and intermittent subjective fevers. Symptoms are worsened with activity and when laying flat. She has no history of similar symptoms in the past.

Vital signs are notable for tachycardia, tachypnea and hypoxia. Examination demonstrates absent breath sounds in the entire right lung field. A plain chest radiograph is obtained and shown below. The patient was placed on non-invasive positive pressure with minimal improvement and an emergent therapeutic thoracentesis was performed. Pleural fluid was exudative and a large volume was submitted for cytology.

Whiteout right lung field

An Algorithm for the Analysis of Pleural Fluid

References

1. Light RW, Girard WM, Jenkinson SG, George RB. Parapneumonic effusions. Am J Med. 1980;69(4):507-512.
2. Heffner JE, Brown LK, Barbieri CA. Diagnostic value of tests that discriminate between exudative and transudative pleural effusions. Primary Study Investigators. Chest. 1997;111(4):970-980. doi:10.1378/chest.111.4.970.
3. Romero S, Martinez A, Hernandez L, et al. Light’s criteria revisited: consistency and comparison with new proposed alternative criteria for separating pleural transudates from exudates. Respiration. 2000;67(1):18-23. doi:10.1159/000029457.
4. Light RW. Clinical practice. Pleural effusion. N Engl J Med. 2002;346(25):1971-1977. doi:10.1056/NEJMcp010731.
5. Sahn SA, Huggins JT, San Jose E, Alvarez-Dobano JM, Valdes L. The Art of Pleural Fluid Analysis. Clinical Pulmonary Medicine. 2013;20(2):77-96. doi:10.1097/CPM.0b013e318285ba37.
6. Light RW. The Light criteria: the beginning and why they are useful 40 years later. Clinics in Chest Medicine. 2013;34(1):21-26. doi:10.1016/j.ccm.2012.11.006.
7. Aggarwal AN, Agarwal R, Sehgal IS, Dhooria S, Behera D. Meta-analysis of Indian studies evaluating adenosine deaminase for diagnosing tuberculous pleural effusion. Int J Tuberc Lung Dis. 2016;20(10):1386-1391. doi:10.5588/ijtld.16.0298.

The post Pleural Fluid appeared first on Differential Diagnosis of.

An approximately 80-year-old male with unknown medical history is brought to the emergency department from a skilled nursing facility after unwitnessed arrest – EMS providers established return of spontaneous circulation after chest compressions and epinephrine. On arrival, the patient was hypotensive (MAP 40mmHg) and hypoxic (SpO2 85%) with mask ventilation. The patient was intubated, resuscitated with intravenous fluids and started on vasopressors. Imaging demonstrated lung consolidation consistent with multifocal pneumonia versus aspiration. Laboratory studies were obtained:

• CBC: WBC: 49.2 (N: 64%, Bands: 20%)
• ABG: pH: 7.07, pCO2: 73mmHg
• Lactate: 9.1mmol/L

ED Course:

The patient was admitted to the medical intensive care unit for cardiopulmonary arrest presumed secondary to hypoxia and septic shock from healthcare-associated pneumonia or aspiration. The markedly elevated white blood cell count was attributed to a combination of infection and tissue ischemia from transient global hypoperfusion.

Definition: ¹

• Markedly elevated leukocyte (particularly neutrophil) count without hematologic malignancy
• Cutoff is variable, 25-50k

Review of Available Literature

Retrospective review of 135 patients with WBC >25k ²

48% infection

15% malignancy

9% hemorrhage

12% glucocorticoid or granulocyte colony stimulating therapy

Retrospective review of 173 patients with WBC >30k ³

48% infection (7% C. difficile)

28% tissue ischemia

7% obstetric process (vaginal or cesarean delivery)

5% malignancy

Observational study of 54 patients with WBC >25k ⁴

Consecutive patients presenting to the emergency department

Compared to age-matched controls with moderate leukocytosis (12-24k)

Patients with leukemoid reaction were more likely to have an infection, be hospitalized and die.

Differential Diagnosis of Leukemoid Reaction ^1,5-8

References

1. Sakka V, Tsiodras S, Giamarellos-Bourboulis EJ, Giamarellou H. An update on the etiology and diagnostic evaluation of a leukemoid reaction. Eur J Intern Med. 2006;17(6):394-398. doi:10.1016/j.ejim.2006.04.004.
2. Reding MT, Hibbs JR, Morrison VA, Swaim WR, Filice GA. Diagnosis and outcome of 100 consecutive patients with extreme granulocytic leukocytosis. Am J Med. 1998;104(1):12-16.
3. Potasman I, Grupper M. Leukemoid reaction: spectrum and prognosis of 173 adult patients. Clin Infect Dis. 2013;57(11):e177-e181. doi:10.1093/cid/cit562.
4. Lawrence YR, Raveh D, Rudensky B, Munter G. Extreme leukocytosis in the emergency department. QJM. 2007;100(4):217-223. doi:10.1093/qjmed/hcm006.
5. Marinella MA, Burdette SD, Bedimo R, Markert RJ. Leukemoid reactions complicating colitis due to Clostridium difficile. South Med J. 2004;97(10):959-963. doi:10.1097/01.SMJ.0000054537.20978.D4.
6. Okun DB, Tanaka KR. Profound leukemoid reaction in cytomegalovirus mononucleosis. JAMA. 1978;240(17):1888-1889.
7. Halkes CJM, Dijstelbloem HM, Eelkman Rooda SJ, Kramer MHH. Extreme leucocytosis: not always leukaemia. Neth J Med. 2007;65(7):248-251.
8. Granger JM, Kontoyiannis DP. Etiology and outcome of extreme leukocytosis in 758 nonhematologic cancer patients: a retrospective, single-institution study. Cancer. 2009;115(17):3919-3923. doi:10.1002/cncr.24480.

The post Leukemoid Reaction appeared first on Differential Diagnosis of.

A middle-aged female with no known medical history is brought to the emergency department with altered mental status. Her family notes worsening confusion over the past 2-3 days associated with vomiting and yellow discoloration of skin and eyes.

Initial vital signs were normal, though with borderline hypotension (99/64mmHg). Examination demonstrated an alert, but lethargic patient with jaundice and scleral icterus, no skin lesions were appreciated. Laboratory studies were obtained:

Imaging:

CT Head: No acute intracranial process.

ED Course:

The patient developed worsening respiratory failure with hypoxia and tachypnea requiring endotracheal intubation. Thrombotic thrombocytopenic purpura was suspected and while awaiting emergent plasma exchange transfusion, the patient arrested and resuscitation efforts were unsuccessful.

The patient’s ADAMTS13 activity level was <3%. Autopsy demonstrated consolidation of the right middle lobe with possible lymphoproliferative mass, and lung petechial hemorrhages from microvascular thrombi.

Differential Diagnosis of Thrombocytopenia ^1-7

Algorithm for the Evaluation of Thrombocytopenia ⁸

Workup ^10,11

Red blood cell fragments (schistocytes) ¹¹

• hCG
• Repeat CBC
  • Detect spurious measure
  • Neutrophil-predominant leukocytosis: bacterial infection
  • Immature leukocytes (blasts): leukemia, myelodysplasia
• Peripheral smear
  • Schistocytes: microangiopathic process (DIC, TTP, HUS)
  • Atypical lymphocytes: viral infection
  • Intracellular parasites: malaria
  • Hypersegmented neutrophils: nutritional deficiency
• Infectious features: HIV, HCV, EBV, H.pylori, blood cultures
• Autoimmune features: ANA, APL-Ab
• Suspected occult liver disease: LFT, PT/PTT/INR
• Suspected thrombotic microangiopathy: PT/PTT/INR, haptoglobin, LDH, fibrinogen, FDP, d-dimer

Specific Conditions ^2-6,9,12-20

References

1. Greinacher A, Selleng S. How I evaluate and treat thrombocytopenia in the intensive care unit patient. Blood. 2016;128(26):3032-3042. doi:10.1182/blood-2016-09-693655.
2. Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Blood. 2017;129(21):2836-2846. doi:10.1182/blood-2016-10-709857.
3. Leslie SD, Toy PT. Laboratory hemostatic abnormalities in massively transfused patients given red blood cells and crystalloid. Am J Clin Pathol. 1991;96(6):770-773.
4. Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190-4207. doi:10.1182/blood-2010-08-302984.
5. Kappler S, Ronan-Bentle S, Graham A. Thrombotic microangiopathies (TTP, HUS, HELLP). Emerg Med Clin North Am. 2014;32(3):649-671. doi:10.1016/j.emc.2014.04.008.
6. Greinacher A. Heparin-Induced Thrombocytopenia. Solomon CG, ed. N Engl J Med. 2015;373(3):252-261. doi:10.1056/NEJMcp1411910.
7. Reardon JE Jr., Marques MB. Evaluation of Thrombocytopenia. Lab Med. 2006;37(4):248-250. doi:10.1309/R7P79KERAJHPRHLT.
8. Stasi R. How to approach thrombocytopenia. Hematology Am Soc Hematol Educ Program. 2012;2012:191-197. doi:10.1182/asheducation-2012.1.191.
9. Gauer RL, Braun MM. Thrombocytopenia. Am Fam Physician. 2012;85(6):612-622.
10. Abrams CS. 172 – Thrombocytopenia. Twenty Fifth Edition. Elsevier Inc.; 2016:1159–1167.e2. doi:10.1016/B978-1-4557-5017-7.00172-0.
11. Wilson CS, Vergara-Lluri ME, Brynes RK. Chapter 11 – Evaluation of Anemia, Leukopenia, and Thrombocytopenia. Second Edition. Elsevier Inc.; 2017:195-234.e195. doi:10.1016/B978-0-323-29613-7.00011-9.
12. Hui P, Cook DJ, Lim W, Fraser GA, Arnold DM. The frequency and clinical significance of thrombocytopenia complicating critical illness: a systematic review. Chest. 2011;139(2):271-278. doi:10.1378/chest.10-2243.
13. Jokiranta TS. HUS and atypical HUS. Blood. 2017;129(21):2847-2856. doi:10.1182/blood-2016-11-709865.
14. Neunert CE. Management of newly diagnosed immune thrombocytopenia: can we change outcomes? Hematology Am Soc Hematol Educ Program. 2017;2017(1):400-405. doi:10.1182/asheducation-2017.1.400.
15. Lambert MP, Gernsheimer TB. Clinical updates in adult immune thrombocytopenia. Blood. 2017;129(21):2829-2835. doi:10.1182/blood-2017-03-754119.
16. Arepally GM. Heparin-induced thrombocytopenia. Blood. 2017;129(21):2864-2872. doi:10.1182/blood-2016-11-709873.
17. Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med. 2007;357(6):580-587. doi:10.1056/NEJMra066469.
18. Boral BM, Williams DJ, Boral LI. Disseminated Intravascular Coagulation. Am J Clin Pathol. 2016;146(6):670-680. doi:10.1093/ajcp/aqw195.
19. Scully M, Hunt BJ, Benjamin S, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012;158(3):323-335. doi:10.1111/j.1365-2141.2012.09167.x.
20. Levine RL, Hursting MJ, Drexler A, Lewis BE, Francis JL. Heparin-induced thrombocytopenia in the emergency department. Ann Emerg Med. 2004;44(5):511-515. doi:10.1016/j.annemergmed.2004.06.004.

The post Thrombocytopenia appeared first on Differential Diagnosis of.

A 27 year-old male with sickle cell disease (HbSC) on hydroxurea and with a history of 2-3 hospitalizations per year for vaso-occlusive pain crises manifested by arthralgias and back pain presents to the emergency department with 3 days of worsening joint pain affecting his entire body but predominantly his knees and lower back. He is familiar with this pain and attempted therapy at home with ibuprofen, then hydrocodone-acetaminophen, and finally hydromorphone without improvement and presented to the emergency department.

On review of systems, he denied chest pain, cough, or shortness of breath. He has some periumbilical abdominal pain but tolerated normal oral intake on the day of presentation without vomiting nor changes in bowel habits. He otherwise denied fevers, peripheral numbness/weakness, urinary or fecal incontinence or retention. He similarly denies trauma, weight loss, night sweats, or intravenous drug use.

Objectively, the patient’s vital signs were normal and he was well-appearing. Mucous membranes were moist and skin turgor was normal. There were no appreciable joint effusions, warmth, nor limitation to active/passive range of motion of any joints. His back had no midline tenderness to palpation or percussion, normal range of motion in all axes and extremity sensation and strength testing were normal. Abdominal and genitourinary examinations were normal. The patient had preserved perineal sensation to light touch and normal rectal tone – a core temperature was obtained which was also normal.

Peripheral access was established and a parenteral dose of hydromorphone equivalent to his home oral dose was administered (0.015mg/kg). Repeat dosing was required at 15 minutes due to persistent pain scale of 10. Diphenhydramine and acetaminophen were also administered, for potential opioid-sparing effects, recognizing the limited evidence to support these relatively benign adjuncts.

Laboratory studies were notable for anemia (though stable compared to baseline measures), appropriate reticulocyte count, no evidence of hemolysis and with normal electrolytes and renal function.

A thorough history and examination did not identify a critical precipitant for the patient’s symptoms which were presumed to be secondary to a vaso-occlusive pain crisis. On reassessment, the patient’s pain was improved and an oral dose of hydromorphone was administered with continued observation and serial reassessments for two hours thereafter. The patient’s hematologist was available for follow-up the subsequent morning and the patient was discharged home.

Pharmacokinetics of Commonly-Used Opiate Analgesics^1-3

Spectrum of Sickle Cell Trait and Disease⁴

Algorithm for the Evaluation and Management of Sickle Cell Crises^4-10

References:

1. Lexicomp Online®, Adult Drug Information, Hudson, Ohio: Lexi-Comp, Inc.; November 4, 2017.
2. Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain Physician. 2008;11(2 Suppl):S133-S153.
3. Vieweg WVR, Lipps WFC, Fernandez A. Opioids and methadone equivalents for clinicians. Prim Care Companion J Clin Psychiatry. 2005;7(3):86-88.
4. Glassberg J. Evidence-based management of sickle cell disease in the emergency department. Emergency Medicine Practice. 2011;13(8):1–20–quiz20.
5. Raam R, Mallemat H, Jhun P, Herbert M. Sickle Cell Crisis and You: A How-to Guide. Ann Emerg Med. 2016;67(6):787-790. doi:10.1016/j.annemergmed.2016.04.016.
6. Piel FB, Steinberg MH, Rees DC. Sickle Cell Disease. N Engl J Med. 2017;376(16):1561-1573. doi:10.1056/NEJMra1510865.
7. Lovett PB, Sule HP, Lopez BL. Sickle cell disease in the emergency department. Emerg Med Clin North Am. 2014;32(3):629-647. doi:10.1016/j.emc.2014.04.011.
8. Yawn BP, John-Sowah J. Management of Sickle Cell Disease: Recommendations From the 2014 Expert Panel Report. Vol 92. 2015:1069-1076.
9. Zempsky WT. Evaluation and Treatment of Sickle Cell Pain in the Emergency Department: Paths to a Better Future. Clinical Pediatric Emergency Medicine. 2010;11(4):265-273. doi:10.1016/j.cpem.2010.09.002.
10. Aliyu ZY, Tumblin AR, Kato GJ. Current therapy of sickle cell disease. Haematologica. 2006;91(1):7-10.

The post Sickle Cell Crises appeared first on Differential Diagnosis of.

• Triggers: infection, acidosis, dehydration, cold-exposure, hypoxia, pregnancy
• Presentation: exclude alternative more serious pathology prior to ascribing pain to vaso-occlusive crisis

Effects by Organ System

Evaluation

• CBC with reticulocyte count
  •  Hemoglobin: suggests sequestration or hemolytic crisis
  • Reticulocyte index: suggests aplastic or megaloblastic crisis
• LDH/haptoglobin: evaluate for hemolysis
• UA: evaluate for infection/infarction
• CXR: evaluate for acute chest syndrome

Management

• Rehydration (hypotonic fluids)
• Analgesia
• Supplemental oxygen if hypoxic
• Exchange transfusion for priapism, neurologic symptoms, aplastic/sequestration/hemolytic crises

Transfusion Reactions

• Epidemiology: overall 0.25%, 0.09% severe
• Management: stop transfusion

Management by Presumed Etiology

The post Hematologic Emergencies appeared first on Differential Diagnosis of.

• Disorders of primary hemostasis
  • General: present with mucocutaneous, post-operative bleeding
  • vWD
  • Platelet disorders
    • Medication-induced: NSAID, valproate, B-lactam, SSRI
    • Systemic disease: hepatic, renal failure
  • ITP: antibody-mediated platelet destruction
• Disorders of secondary hemostasis
  • General: present with bleeding into soft-tissue, joints
  • Hemophilia A (VIII)
  • Hemophilia B (IX)
• Disorders of both primary and secondary hemostasis
  • DIC
  • Liver disease
  • Severe vWD
• Evaluation
  • PT: VII, vitamin K
  • PTT: VIII, IX, XI, XIII, vWD, heparin
  • Increased PT/PTT: XI, V, vitamin K, heparin, DIC
  • CBC: degree of anemia, platelet count, differential (hematopoetic disorders)
• Management
  • Thrombocytopenia
    • Prophylactic transfusion for avoidance of spontaneous hemorrhage for platelet count <10,000
    • Transfusion for active bleeding at platelet count <50,000
    • Dosing
      • Adults: one RDP increases platelet count by 7-10,000
      • Pediatrics: 5-10ml/kg
    • ITP
      • Transfuse platelets for active bleeding
      • High-dose steroids (prednisone 1mg/kg)
      • IVIG (1g/kg/d)
    • Uremia
      • Hemodialysis
      • DDAVP (0.3ug/kg IV)
    • vWD
      • DDAVP (0.3ug/kg IV)
      • Severe: VWF (Humate-P) 40-80IU/kg
      • Tranexamic acid
    • Hemophilia A
      • Minor: 20IU/kg
      • Major: 50IU/kg
    • Hemophilia B
      • Minor: 40IU/kg
      • Major: 100IU/kg

DIC/TTP/HUS

• Disseminated Intravascular Coagulation
  • Etiology: severe systemic illness/injury
    • Trauma, burn, crush
    • Sepsis
    • Malignancy
    • Obstetric complication: abruption, amniotic fluid embolism
    • Hemolytic anemia
  • Exam: petechiae/purpura, hemorrhage (puncture site, GI, GU, pulmonary)
  • Labs:
    • PT/PTT
    • Fibrinogen
    • CBC: schistocytes, thrombocytopenia
    • FDP/D-Dimer
  • Management
    • Treat underlying illness
    • Transfuse (PRBC, FFP for INR > 2, cryoprecipitate for fibrinogen < 100)
    • Heparin if apparent embolic events
    • Consult hematology
• TTP/HUS
  • Presentation
    • Thrombocytopenia
    • Altered mental status
    • Renal dysfunction
    • Fever
    • MAHA
  • TTP: more commonly associated with altered mental status
    • Etiology: drugs, pregnancy, infection (HIV)
    • Mechanism: ULvWF uncleaved by dysfunctional ADAMTS-13
  • HUS: more commonly associated with renal dysfunction
    • Mechanism: toxin from E. coli, Shigella
    • Timing: 1-2wks after diarrheal illness
  • Evaluation
    • CBC: anemia, schistocytes, thrombocytopenia
    • PT/PTT (normal)
    • BUN/Creatinine
    • LDH
  • Management
    • Platelets contraindicated except as stopgap measure in ICH (can worsen process)
    • Plasma exchange with FFP (replaces functional ADAMTS-13)
    • Steroids (prednisone 1mg/kg daily)
    • Hematology consultation

Complications of anti-thrombotic therapy

• Agents
  • Anti-platelet
    • TXA: Aspirin
    • ADP: clopidogrel, ticagrelor, prasugrel
    • GPIIb/IIIa: abciximab, eptifibatide, tirofiban
  • Anti-coagulants
    • Anti-thrombin: heparin, LMWH (enoxaparin, dalteparin)
    • Vitamin K antagonist: warfarn (anti-II, VII, IX, X)
    • Direct thrombin inhibitor: bivalirudin, argatroban, dabigatran
    • Xa inhibitor: rivaroxaban, apixaban
  • Fibrinolytics
    • Alteplase, tenectaplase
• Complications
  • HIT: platelet count decrease >50% at 5 days

Summary of Management

The post Bleeding Disorders appeared first on Differential Diagnosis of.

•  Complications
  • Airway obstruction
  • PNA
  • Pleural effusion
  • Pericardial effusion
  • VTE
  • SVC syndrome
    • Symptoms: dyspnea (airway edema), chest fullness, blurred vision, headache (increased ICP)
  • Massive hemoptysis
    • Management: ETT (large-bore for bronschoscopy), affected side down
• Brain Metastases
  • Cancers: melanoma, lung, breast, colorectal
  • Management: dexamethasone 10mg IV load, elevated HOB, hypertonic saline or mannitol, prophylactic anti-eplipetics
• Meningitis
  • Pathogens: Listeria (ampicillin), Cryptococcus (amphotericin)
  • Evaluation: CSF sampling with cytology (diagnose leptomeningeal metastases)

Metabolic Disturbances

• Hypercalcemia
  • Cancers: MM, RCC, lymphoma, bone metastases (breast, lung, prostate)
  • Mechanism: metastatic destruction, PTH-RP, tumor calcitriol
  • Prognosis: 50% 30-day mortality
  • Symptoms
    • Chronic: anorexia, nausea/vomiting, constipation, fatigue, memory loss
    • Acute: CNS (lethargy, somnolence)
  • Findings
    • Calcium: >13.0mg/dL
    • ECG: QT shortening
  • Treatment
    • Mild: IVF
    • Severe: IVF, loop diuretics, bisophosphanate (pamidronate 90mg IV infused over 4 hours), consider calcitriol, consider hemodialysis if cannot tolerate fluids or unlikely to respond to diuretics
• Hyponatremia
  • Cancers: lung (small-cell), pancreatic, ovarian, lymphoma, thymoma, CNS
  • Mechanism: SIADH
  • Symptoms: muscle twitching, seizure, coma
  • Management: fluid restriction, if seizing administer 3% hypertonic saline at 100cc/hr until resolution
• Hypernatremia
  • Mechanism: decreased intake, increased GI losses from chemotherapy
  • Management: cautious fluid resuscitation
• Tumor Lysis Syndrome (TLS)
  • Cancers: hematologic, rapid-growth solid tumors
  • Mechanism: release of intracellular contents (uric acid, K, PO4, Ca)
  • Timing: 1-4 days after therapy (chemo, radiation)
  • Diagnosis
    • Uric acid >8mg/dL
    • Potassium >6mEq/L
    • Calcium <7mg/dL
    • PO4 >4.5mg/dL
    • Acute kidney injury
  • Management
    • IVF, allopurinol, rasburicase, urinary alkalinization
    • Consider hemodialysis if volume overloaded

Localized Complications

• Musculoskeletal Complications
  • Spinal cord compression
    • Cancers: prostate, breast, lung, RCC, non-Hodgkin lymphoma, MM (5-10% of all cancer patients)
    • Sites: thoracic (60%), lumbosacral (30%), cervical (10%)
    • Symptoms: pain (worse lying flat, cough/sneeze, heavy lifting)
    • Evaluation: MRI (se 93%, sp 97%)
    • Management: dexamethasone 10mg IV load, 4mg q6h, neurosurgical consultation, radiation oncology consultation
  • Pathologic fracture
    • Features: sudden onset, low-force mechanism
• Therapy Complications
  • Neutropenic fever
    • Definition: ANC <500 or ANC <1000 with expected nadir <500 (nadir typically occurs 5-10d after chemotherapy) with Tmax >38.3°C or >38.0°C for >1h
    • Examination: subtle signs of infection, thorough examination is critical (skin, catheter, perineum)
    • Treatment: carbapenem monotherapy, vancomycin if indwelling catheter, oncology consultation for colony stimulating factors
  • Chemotherapy-induced vomiting
    • Management: ondansetron with dexamethasone, consider NK-1 antagonist (aprepitant)

Hematologic Malignancies

• Acute leukemia
  • Signs/Symptoms: leukopenia (infection), anemia (weakness/fatigue), thrombocytopenia (bleeding)
  • Diagnosis: >5% blasts
• Thrombocytopenia
  • Management
    • No bleeding, goal >10,000
    • Fever, coagulopathy, hyperleukoctosis, goal >20,000
    • One unit of platelets increases count by 5,000
• Hyperleukocytosis
  • Definition: WBC > 50-100k
  • Complications: microvascular congestion (pulmonary, cerebral, coronary)
  • Symptoms
    • CNS: confusion, somnolence, coma
    • Pulmonary: dyspnea, respiratory alkalosis
  • Management: cytoreduction (induction chemotherapy, increased risk TLS)
• Hyperviscosity
  • Cancer: macroglobulinemia, MM
  • Symptoms: epistaxis, purpura, GIB, neuro deficits
  • Diagnosis: serum viscosity > 1.4-1.8
  • Management: emergent plasmapheresis
• Polycythemia
  • Diagnosis: Hb >17
  • Differential: dehydration, hypoxia, smoking, altitude
  • Symptoms: HA, vertigo, angina, claudication, pruritus (after showering)
  • Complications: thrombosis (stroke), bleeding
  • Management: emergent phlebotomy (500cc if otherwise healthy)
• Thrombocytosis
  • Diagnosis: platelet >1,000,000
  • Symptoms: vasomotor (HA, lightheadedness, syncope, chest pain, paresthesias)
  • Management: low-dose aspirin

The post Oncologic Emergencies appeared first on Differential Diagnosis of.